Syner-Med first developed and introduced IV Iron Sucrose to Renal Units across the UK in 1994. Since this time, Syner-Med has successfully developed a strong presence and relationship within the Renal arena.

Today, Chronic Kidney Disease (CKD), the progressive loss of kidney function, affects 50million people in the U.S. and Europe alone. Syner-Med provides Renal Units across the world with Catheter Management products to improve Clinical Outcomes and enhance patient welfare. 

Syner-KINASE® (urokinase) is licensed in the UK for the treatment of occluded catheters and systemic thromboembolic occlusive disease (diseases caused by blood clots).

Citra-Lock™ S (trisodium citrate): Anticoagulant and Antimicrobial catheter lock solution to help maintain catheter patency and reduce catheter related infections. The range of pre-filled syringes contain trisodium citrate locking solution available in 4%, 30% & 46.7%.

Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at By reporting side effects you can help provide more information on the safety of this medicine. Adverse events should also be reported to Syner-Med (Pharmaceutical Products) Limited. Tel. +44 020 8655 6380
Subscribe to RSS - Renal

Leave us a message


International headquarters
Syner-Med (Pharmaceutical Products) Ltd.
Syner-Med House
120 High Street
Purley, Surrey
CR8 2AD, United Kingdom

Tel: +44 (0)20 8655 6380